PART 1 PROTEOMICS TECHNOLOGIES Current and emerging mass spectrometry instrumentation and methods for proteomic analyses. Belinda Willard, Suma Kaveti and Michael T. Kinter PART 2 CELL SIGNALING PROTEOMICS 2 Integration of genomics and proteomics in dissecting p53 signaling. Kyunghee Lee, Tao Wang, Abdur Rehman, Yuhua Wang, Sayed S. Daoud 3 Proteomic profiling of tyrosine kinases as pharmacological endpoints for targeted cancer therapy. Moulay A. Alaoui-Jamali and Devanand Pinto PART 3 TUMOR PROTEOMICS Oncoproteomics for personalized management of cancer. K. K. Jain Application of serum and tissue proteomics to understand and detect solid tumors. Christina M. Annunziata, Dana M. Roque, Nilofer Azad, Elise C. Kohn Insight on renal cell carcinoma proteome. Cecilia Sarto, Vanessa Proserpio, Fulvio Magni, Paolo Mocarelli Proteomics in lung cancer. M.A. Reymond, M. Beshay, H. Lippert Proteomic strategies of therapeutic individualization and target discovery in acute myeloid leukemia. Bjørn Tore Gjertsen, Gry Sjøholt New tumor biomarkers: Practical considerations prior to clinical application. Nils Brünner, Mads Holten-Andersen, Fred Sweep, John Foekens, Manfred Schmitt, Michael J Duffy PART 4 BIOINFORMACTICS AND REGULATORY ASPECTS OF PROTEOMICS Annotating the human proteome: From establishing a parts list to a tool for target identification. Rolf Apweiler and Michael Mueller Regulatory aspects of the oncology drug-diagnostics co-development process by proteomics approach. Dave Li, Joseph Hackett, Maria Chan, GenePennello, Steve Gutman
This book covers current topics related to the use of proteomic strategies in cancer therapy as well as anticipated challenges that may arise from its application in daily practice. It details current technologies used in proteomics, examines the use proteomics in cell signaling, presents clinical applications of proteomics in cancer therapy, and looks at the role of the FDA in regulating the use of proteomics.
This comprehensive book provides the reader with broad perspectives and breadth of knowledge on current topics related to the use of proteomic strategies in cancer therapy, as well as anticipated challenges that may arise from its application in daily practice. It begins with the current technologies used in proteomics that allow for protein profiling and for the identification of druggable targets in human samples. The second part deals with the use proteomics in cell signaling. The third part of the book moves from signaling to actual clinical applications of proteomics in cancer therapy. Case studies in many tumor types are provided to show the feasibility of generating the critical information needed to individualization of therapy in cancer patients. The final part of the book provides in depth information on annotating the human proteome and the role of Food and Drug Administration (FDA) in regulating the use of proteomics in cancer therapy.